BOTHELL, Wash., Feb. 4 /PRNewswire-FirstCall/ -- Cardiac Science (Nasdaq: CSCX), a global leader in advanced cardiac diagnosis, resuscitation, rehabilitation, and informatics products, completed a three-year agreement for product design and engineering services from Colorado-based Syncroness, a leading design and engineering firm serving the medical devices industry.
"We expect considerable savings and speed-to-market improvements with Syncroness," said Bob Odell, vice president of engineering for Cardiac Science. The agreement increases Cardiac Science's engineering capacity to manage sustaining activities and new business opportunities. Odell adds, "This will allow seasoned Cardiac Science team members to focus on new customer solutions, revenue opportunities, and new advances in technology. As a result, we'll be even faster and more responsive to market needs."
"We've worked with Cardiac Science on a smaller scale and I can say they are a great partner," said chief marketing officer Jorg Lorscheider. "I'm confident we will reward Cardiac Science's trust with lowered costs, product development efficiencies, and an improved speed-to-market."
About Cardiac Science
Cardiac Science develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AEDs), electrocardiograph devices (ECGs), cardiac stress systems and treadmills, Holter monitoring systems, hospital defibrillators, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick(R), HeartCentrix(R), Powerheart(R), and Quinton(R) brands, is headquartered in Bothell, Washington. With customers in more than 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.
Syncroness (Westminster, CO) is a leading product design firm and a pioneer in the development of advanced business processes for engineering that increase profit and performance for the organizations we serve. For information, call 877.429.5005 or visit http://www.syncroness.com.
This press release contains forward-looking statements. The words "believe," "expect," "intend," "anticipate," variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. Forward-looking statements in this press release include, but are not limited to, those relating to Cardiac Science Corporation's expectations regarding cost savings or improved research and development capabilities and the resulting impact on operating results. These are forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause or contribute to such varying results and other risks are more fully described in Cardiac Science Corporation's Annual Report on Form 10-K for the year ended December 31, 2007 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2008. Cardiac Science Corporation undertakes no duty or obligation to update the information provided herein.
For more information, Company Contact: Mike Matysik Cardiac Science Corporation Senior Vice President and CFO 425.402.2009 Investor Contact: Doug Sherk Jenifer Kirtland EVC Group Inc. 415.896.6820 Media Contact: Christopher Gale EVC Group Inc. 646.201.5431 203.570.4681 email@example.com CSCX-G
|SOURCE Cardiac Science|
Copyright©2009 PR Newswire.
All rights reserved